Trial Outcomes & Findings for Quatera 700 vs. Centurion (NCT NCT06225362)
NCT ID: NCT06225362
Last Updated: 2026-04-01
Results Overview
Ultrasound pachymetry
Recruitment status
COMPLETED
Study phase
NA
Target enrollment
80 participants
Primary outcome timeframe
Postoperative day 1
Results posted on
2026-04-01
Participant Flow
This was a split-eye study design. Each participant contributed two eyes, with one eye assigned to each intervention arm. Therefore, participants appear in both arms and may be counted more than once across arms in the Participant Flow table.
Unit of analysis: Eyes
Participant milestones
| Measure |
Quatera 700
Quatera 700 phacoemulsification device
|
Centurion
Centurion phacoemulsification device
|
|---|---|---|
|
Overall Study
STARTED
|
40 40
|
40 40
|
|
Overall Study
COMPLETED
|
40 40
|
40 40
|
|
Overall Study
NOT COMPLETED
|
0 0
|
0 0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Quatera 700 vs. Centurion
Baseline characteristics by cohort
| Measure |
Overall
n=40 Participants
Baseline demographic characteristics were collected at the participant level. This was a split-eye study in which each participant contributed two eyes, with one eye assigned to each intervention arm. Therefore, baseline characteristics are reported once for the overall participant population rather than separately by intervention arm.
|
|---|---|
|
Age, Continuous
|
70.7 years
STANDARD_DEVIATION 6.3 • n=5 Participants
|
|
Sex: Female, Male
Female
|
32 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
8 Participants
n=5 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Black or African American
|
4 Participants
n=5 Participants
|
|
Race (NIH/OMB)
White
|
36 Participants
n=5 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
PRIMARY outcome
Timeframe: Postoperative day 1Ultrasound pachymetry
Outcome measures
| Measure |
Quatera 700
n=40 Participants
Quatera 700: Phacoemulsification device
|
Centurion Vision System
n=40 Participants
Centurion: Phacoemulsification device
|
|---|---|---|
|
Central Corneal Thickness
|
572.8 microns
Standard Deviation 49.4
|
565.6 microns
Standard Deviation 42.9
|
PRIMARY outcome
Timeframe: Intraoperativefrom end of rhexis to complete nucleus removal
Outcome measures
| Measure |
Quatera 700
n=38 Participants
Quatera 700: Phacoemulsification device
|
Centurion Vision System
n=37 Participants
Centurion: Phacoemulsification device
|
|---|---|---|
|
Lens Removal Time
|
129.8 seconds
Standard Deviation 56.0
|
77.7 seconds
Standard Deviation 22.2
|
Adverse Events
Quatera 700
Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths
Centurion
Serious events: 0 serious events
Other events: 4 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Quatera 700
n=40 participants at risk
Quatera 700 phacoemulsification device
|
Centurion
n=40 participants at risk
Centurion phacoemulsification device
|
|---|---|---|
|
Eye disorders
Superficial Punctate Keratitis
|
7.5%
3/40 • Number of events 3 • 3 months
|
10.0%
4/40 • Number of events 4 • 3 months
|
Additional Information
Director of Clinical Trials
Carolina Eyecare Physicians, LLC
Phone: 8438813937
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place